- Alignment Healthcare Set to Join S&P SmallCap 600
May 11, 2026
NEW YORK, May 11, 2026 /PRNewswire/ -- Alignment Healthcare Inc. (NASD: ALHC) will replace Sun Country Airlines Holdings Inc. (NASD: SNCY) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14. S&P SmallCap 600 constituent Allegiant Travel Co. (NASD: ALGT) is acquiring Sun Country Airlines Holdings in a deal expected to close soon, pending final closing conditions.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date Index Name Action Company Name Ticker GICS Sector May 14, 2026 S&P SmallCap 600 Addition Alignment Healthcare ALHC Health Care May 14, 2026 S&P SmallCap 600 Deletion Sun Country Airlines Holdings SNCY Industrials
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.
FOR MORE INFORMATION:
S&P Dow Jones Indices index_services@spglobal.com
Media Inquiries spdji.comms@spglobal.comCision
View original content:https://www.prnewswire.com/news-releases/alignment-healthcare-set-to-join-sp-smallcap-600-302768757.html
View Comments
- Alignment Healthcare Set to Join S&P SmallCap 600
May 11, 2026 · prnewswire.com
NEW YORK, May 11, 2026 /PRNewswire/ -- Alignment Healthcare Inc. (NASD: ALHC) will replace Sun Country Airlines Holdings Inc. (NASD: SNCY) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14. S&P SmallCap 600 constituent Allegiant Travel Co. (NASD: ALGT) is acquiring Sun Country Airlines Holdings in a deal expected to close soon, pending final closing conditions.
- ALIGNMENT HEALTHCARE SET TO JOIN S&P SMALLCAP 600
May 11, 2026
NEW YORK, MAY 11, 2026 /PRNEWSWIRE/ -- ALIGNMENT HEALTHCARE INC. (NASD: ALHC) WILL REPLACE SUN COUNTRY AIRLINES HOLDINGS INC. (NASD: SNCY) IN THE S&P SMALLCAP 600 EFFECTIVE PRIOR TO THE OPENING OF TRADING ON THURSDAY, MAY 14. S&P SMALLCAP 600 CONSTITUENT ALLEGIANT TRAVEL CO. (NASD: ALGT) IS ACQUIRING SUN COUNTRY AIRLINES HOLDINGS IN A DEAL EXPECTED TO CLOSE SOON, PENDING FINAL CLOSING CONDITIONS.
- Enrich Your Portfolio With These 4 Top-Ranked Liquid Stocks
May 6, 2026
Liquidity measures a company’s capability to meet short-term debt obligations. Investors seeking strong portfolio returns should benefit from adding stocks with sound liquidity, which encourages business growth. Stocks with high liquidity levels have always been in demand, owing to their potential to provide maximum returns.
Investors may want to consider adding four top-ranked stocks — Alignment Healthcare, Inc. ALHC, Argan, Inc. AGX, Ciena Corporation CIEN and Silicon Motion Technology Corporation SIMO — to their portfolios to boost returns.
However, it is important to exercise caution. While high liquidity can indicate that a company is efficiently managing its short-term obligations, it may also suggest underutilization of resources. In some cases, companies with excess liquidity may not be deploying their assets effectively, which could limit growth potential.
Hence, one may consider a company’s efficiency level in addition to its liquidity while identifying prospective winners. A balanced assessment of both liquidity and efficiency can help identify truly promising investment opportunities.
Measures to Identify Liquid Stocks
Current Ratio: It measures current assets relative to current liabilities. The ratio gauges a company’s potential to meet short and long-term debt obligations. A current ratio — the working capital ratio — below 1 indicates that the company has more liabilities than assets. A high current ratio does not always suggest that the company is in good financial shape. It may also indicate that the firm failed to utilize its assets significantly. Hence, a range of 1-3 is considered ideal.
Quick Ratio: Unlike the current ratio, the quick ratio — the “acid-test ratio” or “quick assets ratio” — indicates a company’s ability to pay short-term obligations. It considers inventory, excluding current assets, relative to current liabilities. A quick ratio of more than 1 is desirable, like the current ratio.
Cash Ratio: This is the most conservative ratio among the three, considering cash, cash equivalents and invested funds relative to current liabilities. It measures a company’s ability to meet existing debt obligations using the most liquid assets. Though a cash ratio of more than 1 may suggest sound financials, a higher number may indicate inefficiency in cash utilization.
A ratio greater than 1 is always desirable, but it may not always represent a company’s financial condition.
Screening Parameters
To pick the best of the lot, we have added asset utilization — a widely used measure of a company’s efficiency — as one of the screening criteria. Asset utilization is the ratio of total sales in the past 12 months to the last four-quarter average of total assets. Though this ratio varies across industries, companies with a ratio higher than that of their industry can be considered efficient.
Story Continues
We added our proprietary Growth Score to the screen to ensure these liquid and efficient stocks have solid growth potential.
Current Ratio, Quick Ratio, and Cash Ratio between 1 and 3: While liquidity ratios greater than 1 are desirable, significantly high ratios may indicate inefficiency.
Asset utilization is more significant than the industry average: A higher asset utilization than the industry average indicates a company’s efficiency.
Zacks Rank equal to #1 (Strong Buy): Only Strong Buy-rated stocks can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.
Growth Score less than or equal to B: Back-tested results show that stocks with a Growth Score of A or B handily beat other stocks when combined with a Zacks Rank #1 or 2 (Buy).
These criteria have narrowed the universe of more than 7,700 stocks to only five.
Here are four of the five stocks that qualified the screen:
Alignment Healthcare is a clinically focused platform designed to improve the healthcare experience for seniors registered under Medicare. Through its various Medicare Advantage plans, it caters to the various requirements and preferences of seniors.
The company recently reported first-quarter 2026 results, wherein revenues came in at $1.24 billion, up 33.3% year over year. Performance was driven by strength and execution across sales, clinical operations and member retention. At quarter-end, health plan membership was 284,800, up 30.9% from the prior year quarter.
Profitability numbers were also impressive, with adjusted EBITDA up 87.6% year over year to $37.9 million. 2026 revenues are now expected to be between $5.16 billion and $5.21 billion.
The Zacks Consensus Estimate for ALHC’s 2026 earnings stands at 15 cents per share, up 2 cents in the past seven days. The company has a Growth Score of A and a trailing four-quarter earnings surprise of 198.81%, on average.
Argan offers comprehensive construction and related services to the power industry through its Gemma Power Systems and Atlantic Projects company operations.
Driven by a strong demand backdrop, AGX reported fiscal 2026 revenues of $944.6 million, up 8.1% year over year. It ended the year with a backlog of $2.9 billion, after adding $2.5 billion in new contract value. Demand for its services is being driven by growth in AI and data centers and the replacement of aging power infrastructure.
The company is also maintaining a strong capital allocation strategy and returned $43 million to shareholders in fiscal 2026.
The Zacks Consensus Estimate for AGX’s fiscal 2027 earnings stands at $11.44 per share, unchanged in the past seven days. The company has a Growth Score of A.
Ciena, headquartered in Hanover, MD, is a leading provider of optical networking equipment, software and services.
Driven by accelerating AI-led demand from cloud and service provider customers, Ciena’s top line in the first quarter of 2026 improved 33% year over year, the bottom line grew 111%, and order backlog was a record $7 million. Ciena continues to capitalize on WAN connectivity needs across subsea, long-haul, metro networks and DCI.
Better pricing, Hyper-Rail innovation and cost optimization are expected to boost gross margins, going ahead. For fiscal 2026, adjusted gross margins are projected at 43.5-44.5%. With the first half exceeding expectations and supply challenges being managed, Ciena now expects first and second-half gross margins to be roughly similar. It is managing supply conditions effectively and expanding capacity, but demand is expected to exceed supply for the next several quarters.For the second quarter, Ciena expects revenues of $1.5 billion (+/-$50 million).
The Zacks Consensus Estimate for CIEN’s fiscal 2026 earnings is pegged at $6.16 per share, up one cent in the past seven days. The company has a Growth Score of A and a trailing four-quarter earnings surprise of 11.6%, on average.
Silicon Motion Technology is a leading developer of microcontroller ICs for NAND flash storage devices.
The company recently reported first-quarter 2026 results, wherein revenues came in at $342.1 million, up 23% sequentially and 105% year over year. The strong performance was buoyed by growth in embedded eMMC and UFS controllers as well as sharp acceleration in Ferri and boot drive offerings, highlighting expanding traction in enterprise and AI-related markets.
Given strong top-line expansion, non-GAAP operating income climbed sharply to $62.2 million from $14.9 million in the prior year quarter, with operating margin expanding to 18.2% from 8.9%. Increasing exposure to new enterprise/AI opportunities is likely to sustain long-term growth.
The Zacks Consensus Estimate for SIMO’s 2026 earnings is pegged at $7.81 per share, up from $5.78 in the past seven days. The company has a Growth Score of B and a trailing four-quarter earnings surprise of 18.61%, on average.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ciena Corporation (CIEN) : Free Stock Analysis Report
Silicon Motion Technology Corporation (SIMO) : Free Stock Analysis Report
Argan, Inc. (AGX) : Free Stock Analysis Report
Alignment Healthcare, Inc. (ALHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Enrich Your Portfolio With These 4 Top-Ranked Liquid Stocks
May 6, 2026 · zacks.com
ALHC, AGX, CIEN, and SIMO make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.
- Can Alignment Healthcare (ALHC) Climb 32.61% to Reach the Level Wall Street Analysts Expect?
May 5, 2026
Shares of Alignment Healthcare (ALHC) have gained 3.2% over the past four weeks to close the last trading session at $19.26, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.54 indicates a potential upside of 32.6%.
The average comprises 13 short-term price targets ranging from a low of $19.00 to a high of $30.00, with a standard deviation of $2.82. While the lowest estimate indicates a decline of 1.4% from the current price level, the most optimistic estimate points to a 55.8% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for ALHC, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS SurpriseZacks Price, Consensus and EPS Surprise Chart for ALHC
Here's What You Should Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
Story Continues
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why ALHC Could Witness a Solid Upside
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 16.9% over the past month, as three estimates have gone higher compared to no negative revision.
Moreover, ALHC currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much ALHC could gain, the direction of price movement it implies does appear to be a good guide.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alignment Healthcare, Inc. (ALHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Can Alignment Healthcare (ALHC) Climb 32.61% to Reach the Level Wall Street Analysts Expect?
May 5, 2026 · zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 32.6% in Alignment Healthcare (ALHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Alignment Healthcare, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 3, 2026
Shareholders might have noticed that Alignment Healthcare, Inc. (NASDAQ:ALHC) filed its first-quarter result this time last week. The early response was not positive, with shares down 4.1% to US$20.26 in the past week. Revenues were US$1.2b, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$0.05, an impressive 502% ahead of estimates. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGS:ALHC Earnings and Revenue Growth May 3rd 2026
Taking into account the latest results, the current consensus from Alignment Healthcare's twelve analysts is for revenues of US$5.18b in 2026. This would reflect a sizeable 22% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to surge 82% to US$0.17. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$5.17b and earnings per share (EPS) of US$0.13 in 2026. Although the revenue estimates have not really changed, we can see there's been a considerable lift to earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.
See our latest analysis for Alignment Healthcare
There's been no major changes to the consensus price target of US$25.54, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Alignment Healthcare, with the most bullish analyst valuing it at US$30.00 and the most bearish at US$19.00 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Alignment Healthcare shareholders.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Alignment Healthcare'shistorical trends, as the 30% annualised revenue growth to the end of 2026 is roughly in line with the 30% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 4.8% per year. So although Alignment Healthcare is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
Story Continues
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Alignment Healthcare following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Alignment Healthcare analysts - going out to 2028, and you can see them free on our platform here.
You still need to take note of risks, for example - Alignment Healthcare has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- ALHC Q1 Deep Dive: Membership Growth and Margin Expansion Offset by Cautious Guidance
May 3, 2026
Health insurance company Alignment Healthcare (NASDAQ:ALHC) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 33.3% year on year to $1.24 billion. On the other hand, next quarter’s revenue guidance of $1.31 billion was less impressive, coming in 0.9% below analysts’ estimates. Its non-GAAP profit of $0.12 per share was 38.7% above analysts’ consensus estimates.
Is now the time to buy ALHC? Find out in our full research report (it’s free).
Alignment Healthcare (ALHC) Q1 CY2026 Highlights:
Revenue: $1.24 billion vs analyst estimates of $1.22 billion (33.3% year-on-year growth, 1.3% beat) Adjusted EPS: $0.12 vs analyst estimates of $0.09 (38.7% beat) Adjusted EBITDA: $37.85 million vs analyst estimates of $32.51 million (3.1% margin, 16.4% beat) The company slightly lifted its revenue guidance for the full year to $5.18 billion at the midpoint from $5.16 billion EBITDA guidance for the full year is $150.5 million at the midpoint, in line with analyst expectations Operating Margin: 1.3%, up from -0.6% in the same quarter last year Customers: 284,800, up from 236,300 in the previous quarter Market Capitalization: $4.66 billion
StockStory’s Take
Alignment Healthcare’s first quarter was marked by robust membership growth and improved operating margins, but the market response was negative, likely due to concerns over operational hiccups and the sustainability of recent gains. Management emphasized that strong sales execution and disciplined member retention were key to driving growth, with CEO John Kao noting, “Our results this quarter reflect strong execution across sales and member retention as well as our clinical operations.” The company also highlighted rapid progress in claims automation and technology investments as contributors to improved efficiency, though a temporary workflow issue related to inpatient admissions modestly pressured medical costs during the quarter.
Looking ahead, Alignment Healthcare’s updated guidance reflects a focus on scaling efficiently while managing cost pressures in a shifting policy environment. Management cited disciplined investments in automation and technology to improve claim processing, contract management, and clinical engagement. CFO James Head cautioned that while the company is investing in growth and infrastructure, it is maintaining a cautious approach to new member risk adjustment and product mix. The company plans to expand into additional markets but highlighted the need for operational readiness and ongoing scrutiny of policy changes, especially regarding Medicare Advantage rate updates and risk model evolutions.
Story Continues
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to disciplined sales and retention, ongoing technology investments, and operational agility amid policy and workflow changes.
Membership expansion: The company experienced significant membership growth, driven by strong open enrollment performance and retention initiatives, with an emphasis on medically complex populations that benefit from Alignment’s clinical model. Claims automation progress: Investments in automation resulted in claims auto-adjudication rates rising from under 15% to over 60% year-over-year, reducing administrative costs and improving overall efficiency. Workflow disruption and resolution: A CMS rule change led to a temporary workflow issue—overpaying for certain hospital admissions—that was identified and corrected within a month, demonstrating the company’s ability to respond quickly to operational challenges. Shift toward higher acuity members: Growth in special needs populations (SNPs) was intentional, with management highlighting the long-term margin potential as these members mature and transition into the loyal customer base. Technology and AI investments: The company is deploying AI-driven contract management and clinical risk stratification tools, aiming to further reduce SG&A and medical care ratios while improving care quality and scalability.
Drivers of Future Performance
Alignment’s outlook centers on continued operational scaling, targeted investments in automation, and navigating regulatory changes affecting Medicare Advantage.
Scaling automation and AI: Management is prioritizing increased automation in claims and contract management, expecting these initiatives to enhance operational leverage and lower administrative expenses over time. Population mix and risk modeling: The company’s focus on acquiring more medically complex members may temporarily elevate medical costs, but management expects margin tailwinds as these members become established and as risk adjustment processes mature. Regulatory and policy headwinds: Ongoing changes in Medicare Advantage policies and risk model updates present uncertainties, with management highlighting the importance of adaptability as CMS pursues greater program accountability and cost containment.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) further improvements in claims automation and their impact on SG&A efficiency, (2) the integration and performance of new, higher-acuity members as they mature within the plan, and (3) Alignment Healthcare’s execution on entering new markets while maintaining disciplined cost controls. Developments in Medicare Advantage policy and risk model updates will also be key indicators of future performance.
Alignment Healthcare currently trades at $19.69, down from $22.54 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
High Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
View Comments
- Why Alignment Healthcare (ALHC) Is Up 8.2% After Returning To Profitability And Raising 2026 Guidance
May 1, 2026
In the first quarter of 2026, Alignment Healthcare, Inc. reported revenue of US$1,235.2 million, up from US$926.93 million a year earlier, and moved from a net loss to net income of US$11.42 million, with earnings per share turning positive. The company paired this shift to profitability with 33.3% year-over-year revenue growth and a 30.9% increase in Medicare Advantage membership, while slightly raising full-year guidance across membership, revenue, adjusted gross profit and adjusted EBITDA. We’ll now examine how the return to profitability and raised full-year guidance could reshape Alignment Healthcare’s broader investment narrative.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
Alignment Healthcare Investment Narrative Recap
To own Alignment Healthcare, I think you need to believe its tech-enabled Medicare Advantage model can translate rapid membership gains into durable, profitable growth despite shifting regulation and reimbursement. The Q1 2026 return to profitability and raised full-year guidance support that thesis, but also sharpen the near term catalyst and risk: how well the company can sustain margin discipline while operating under evolving Medicare rules and reimbursement frameworks. For now, this earnings beat appears directionally positive, not thesis-changing.
Among recent developments, the US$256.2 million follow-on equity offering in March 2026 stands out alongside the Q1 results, because it expands Alignment’s financial flexibility just as membership, revenue and adjusted EBITDA guidance are moving higher. That stronger balance sheet could matter if medical costs, policy pressures, or competitive intensity rise more than expected, affecting how confidently the company can keep investing in growth and technology while managing near term profitability targets.
Yet in contrast, investors should also be aware that if Medicare Advantage reimbursement or risk adjustment tightens more than expected, Alignment’s margin story could...
Read the full narrative on Alignment Healthcare (it's free!)
Alignment Healthcare’s narrative projects $8.0 billion revenue and $151.5 million earnings by 2029. This requires 26.5% yearly revenue growth and about a $152.2 million earnings increase from -$724.0 thousand today.
Uncover how Alignment Healthcare's forecasts yield a $25.50 fair value, a 13% upside to its current price.
Exploring Other PerspectivesALHC 1-Year Stock Price Chart
Some of the most optimistic analysts were already modeling around US$9.2 billion in 2029 revenue and roughly US$195 million in earnings, so this latest profitability step may either reinforce that upbeat view or prompt a rethink of how quickly those outcomes might reasonably be reached.
Story Continues
Explore 2 other fair value estimates on Alignment Healthcare - why the stock might be worth just $25.50!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
A great starting point for your Alignment Healthcare research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Our free Alignment Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alignment Healthcare's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALHC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
